azd2014 for treating er metastatic breast cancer – mode of action and trial results
Published 8 years ago • 137 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
1:56
vepdegestrant palbociclib in er metastatic breast cancer: phase ib trial results
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
17:54
expert perspectives: cdk 4/6 inhibitors for er breast cancer: current data and clinical use
-
7:36
asco 2022: metastatic breast cancer drug therapy recap
-
7:23
study of ribociclib and pdr001 in hr metastatic breast cancer
-
2:03
emerald: elacestrant vs. soc for patients with er her2- metastatic breast cancer
-
1:52:27
treating metastatic breast cancer
-
4:14
er degrader safe, with signs of antitumour activity against er-positive breast cancer
-
49:09
metastatic breast cancer forum 2018: her2-positive breast cancer | dana-farber cancer institute
-
2:24
identifying drivers of first-line hr /her2- metastatic breast cancer treatment choices
-
2:15
treatment strategies for her2 metastatic breast cancer
-
6:29
study of palbociclib after cdk & endocrine therapy in er /her2- metastatic breast cancer
-
3:24
evolving treatment options in er metastatic breast cancer
-
0:30
stages of breast cancer
-
1:18:51
medical advances in the treatment of metastatic breast cancer
-
3:58
promise breast cancer clinical trial
-
1:02:23
balancing act: treatment choices and side effects in metastatic breast cancer
-
1:25:11
breast cancer trials q&a: metastatic breast cancer
-
26:11
live webchat: choosing a clinical trial for metastatic breast cancer